Atlanta: Diwakar Tejaswi, Senior Physician from Patna, has presented emerging evidence on the use of doxycycline for preventing certain bacterial sexually transmitted infections (STIs) at the IDWeek 2025 conference in Atlanta.
According to Dr. Tejaswi, international studies indicate that generic doxycycline, when used as post-exposure prophylaxis within 72 hours of sexual contact—or, in some trials, as pre-exposure prophylaxis in high-risk groups—can substantially reduce the incidence of syphilis and chlamydia, while partially lowering the risk of gonorrhoea.
Dr. Tejaswi emphasised that such interventions should always be implemented under medical supervision, with regular STI testing and careful monitoring for antibiotic resistance.
“While doxycycline shows promise, responsible usage and ongoing research are essential to prevent resistance and ensure patient safety,” he said.
